Issue link: https://uberflip.scri.com/i/1529641
1125/24SCR018-7/R3 Abstract & Presentation Calendar ASH® 2024 5 Saturday Sunday Monday SUNDAY, DECEMBER 8 TH 4:30pm - 8:00pm Pacific Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 4:30 - 6:00pm 4:30pm Manchester Grand Hyatt, Grand Hall D Oral 655 Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients El Chaer F Rotta M Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis 4:30 - 6:00pm 5:15pm San Diego Convention Center, Room 6A Oral 694 Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients Oliai CH Pantin J Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 3756 Symptoms Detection Among Patients with Lymphoid Malignancies (LM) Using Electronic Patient-Reported Outcomes (ePROs) in Community Hematology-Oncology Clinics Ahmed S (Essell JH presenting) Essell JH Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 3734 The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin's Lymphoma (NHL) - a Large, Multicenter Study Battiwalla M Battiwalla M, Blunk B, Martin C, Mattlin M, Hsu H, Farhadfar N, Tees MT, Rao UK, Mathews J, Billups RL, Cox T, Majhail N Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 3008 Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low- Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study Burke JM Burke JM Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 3101 Durability of Complete Responses in Patients from the ECHELON-3 Study Yasenchak C Yasenchak C Aggressive Lymphomas: Pharmacologic Therapies: Poster II 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 3237 CRISTALLO: Results from a Phase III Trial of Venetoclax Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine + Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations Sharman JP Sharman JP Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4483 Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study Bartlett NL Yasenchak C Aggressive Lymphomas: Pharmacologic Therapies: Poster II 6:00 - 8:00pm San Diego Convention Center, Halls G-H Poster 4489 Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study Hahn U Yasenchak C Aggressive Lymphomas: Pharmacologic Therapies: Poster II